If you have been reading about growth hormone peptides for stubborn belly fat, tesamorelin sits in a category of its own: it is the only GHRH analog with FDA approval and Phase 3 trial data proving it reduces visceral adipose tissue. The standard dose is 2 mg injected subcutaneously once daily.
In two pivotal trials totaling over 800 participants, tesamorelin 2 mg/day reduced visceral fat by 15 to 18% over 26 weeks, measured by CT scan (Falutz et al., NEJM 2007). That is a meaningful reduction in the deepest, most metabolically dangerous fat depot, achieved without caloric restriction or structured exercise programs.
Quick reference: tesamorelin dosing protocol
Dose
2 mg (2,000 mcg)
Frequency
Once daily
Route
Subcutaneous injection
Timing
Morning, on an empty stomach
Cycle length
12 to 26 weeks
FDA indication
HIV-associated lipodystrophy
Use our reconstitution calculator to determine exact injection volumes for your vial size. For dosage reference across all peptides, see the complete peptide dosage chart.
Tesamorelin (brand name Egrifta) carries FDA approval specifically for reducing excess abdominal fat in HIV-positive adults with lipodystrophy. Off-label use for general fat loss is not FDA-approved. All information below is educational. Consult a qualified healthcare provider before acting on any dosage information. For broader context on peptide safety, see the peptide safety guide.
Get your custom peptide protocol:
Tailored to your body and goals
Precise dosing and cycle length
Safe stacking combinations
Backed by peer-reviewed studies
Ready in under 2 minutes
What Is Tesamorelin and How Does It Work?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the 44-amino-acid peptide your hypothalamus secretes to tell your pituitary gland to produce growth hormone. Theralogics (now Theratechnologies) developed it by attaching a trans-3-hexenoic acid group to the tyrosine at position 1, which protects the molecule from enzymatic degradation and extends its half-life to approximately 26 minutes after subcutaneous injection (Stanley & Bhatt, Expert Opin Pharmacother 2012).
That modification is the key differentiator. Natural GHRH has a plasma half-life under 7 minutes, far too short to produce a sustained physiological effect from a single injection. Tesamorelin lasts long enough to stimulate a full pulsatile GH release from the anterior pituitary.
Here is how the downstream cascade works. Tesamorelin binds GHRH receptors on somatotroph cells in the pituitary. Those cells release growth hormone into the bloodstream. GH then acts on adipose tissue directly and through insulin-like growth factor-1 (IGF-1) to increase lipolysis, the breakdown of stored triglycerides into free fatty acids. Visceral fat is particularly sensitive to GH-mediated lipolysis because it has a higher density of beta-adrenergic receptors and greater blood flow than subcutaneous fat (Møller & Jørgensen, Endocr Rev 2009).
Think of it like a thermostat for your growth hormone. Rather than injecting synthetic GH directly (which floods the system with a flat, unnatural spike), tesamorelin tells your pituitary to release GH in its normal pulsatile pattern. The body still controls how much GH is released, which is why side effects are milder than with exogenous GH injections.
Tesamorelin vs Exogenous Growth Hormone
The distinction matters clinically. Exogenous GH (somatropin) delivers a fixed dose that bypasses the pituitary entirely. This often raises IGF-1 levels above the physiological range, increasing the risk of edema, joint pain, carpal tunnel syndrome, and insulin resistance.
Tesamorelin stimulates endogenous GH release, which means the pituitary retains its negative feedback loop. When GH and IGF-1 rise, somatostatin signals the pituitary to slow down. This self-regulating mechanism keeps levels closer to the physiological ceiling (Dhillon, Drugs 2011).
Mechanism
Direct GH replacement
Stimulates pituitary GH release
GH pattern
Flat, supraphysiological spike
Pulsatile, physiological
Feedback loop
Suppressed
Preserved
IGF-1 elevation
Often supraphysiological
Usually within range
Insulin resistance risk
Higher
Lower
Joint pain/edema
Common at therapeutic doses
Less common
For researchers comparing growth hormone secretagogues, our peptide stacking guide covers how tesamorelin fits alongside other GH peptides.
FDA-Approved Tesamorelin Dosage: 2 mg/Day
The FDA-approved dose is 2 mg (2,000 mcg) injected subcutaneously once daily. This dose was established through Phase 2 dose-ranging studies and confirmed in two Phase 3 pivotal trials.
There is no titration schedule. Unlike GLP-1 agonists that require weeks of dose escalation, tesamorelin starts at the full therapeutic dose from day one. The rationale: tesamorelin works through the body's own regulatory system, so the pituitary modulates the response naturally.
Phase 3 Trial Results: Visceral Fat Reduction
Two pivotal Phase 3 trials established the efficacy of the 2 mg dose. Both enrolled HIV-positive adults with excess abdominal fat (lipodystrophy), as measured by CT scan at baseline.
Trial 1 (TH9507-CT-SEROST-0502): 412 participants randomized to tesamorelin 2 mg or placebo for 26 weeks (Falutz et al., NEJM 2007):
Visceral fat change (trunk)
-15.2%
+5.0%
IGF-1 increase
+81.3 ng/mL
+2.2 ng/mL
Body weight change
-0.5 kg
+0.3 kg
Triglycerides change
-50 mg/dL
-9 mg/dL
Trial 2 (TH9507-CT-SEROST-0504): 404 participants, same design (Falutz et al., JAIDS 2010):
-18.0%
+3.8%
Limb fat
No significant change
Lean body mass
+1.3 kg
-0.1 kg
Two things stand out. First, tesamorelin selectively targets visceral fat while preserving limb fat and lean mass. Second, the visceral fat reduction was consistent across both trials: roughly 15 to 18% in 26 weeks. For a peptide that does not require caloric restriction, those numbers are clinically significant.
Extension Study: 52-Week Data
An open-label extension followed participants for an additional 26 weeks (52 weeks total). Among those who continued tesamorelin, visceral fat reduction was maintained. Among those switched from tesamorelin to placebo at week 26, visceral fat returned to near-baseline levels within 3 months (Falutz et al., JAIDS 2010).
This finding has practical implications: tesamorelin's fat-reducing effect depends on continued use. Stopping the peptide leads to visceral fat reaccumulation. The data suggest ongoing or cyclical use is necessary to maintain results.
Tesamorelin for 52 weeks
Maintained 15-18% reduction
Tesamorelin 26 weeks then placebo
Returned to near baseline
Placebo then tesamorelin (crossover)
15% reduction from crossover start
This rebound pattern is consistent across GH-based therapies. Growth hormone increases lipolysis actively; when the stimulus is removed, the metabolic environment returns to its prior state. Planning for this reality is essential, and we cover cycling strategies in detail below.
Off-Label Dosing Protocols for General Fat Loss
Outside the HIV lipodystrophy indication, clinicians at anti-aging and optimization clinics prescribe tesamorelin off-label for general visceral fat reduction. The dose remains 2 mg/day in most protocols, consistent with the FDA-approved regimen.
Some practitioners use a lower dose of 1 mg/day as a starting point for patients new to GH peptides, particularly those with lower body weight or those concerned about cost. No controlled trial has evaluated 1 mg/day head-to-head against 2 mg/day for fat loss. The available pharmacokinetic data suggest that 1 mg produces a smaller GH pulse, so the lipolytic effect is proportionally reduced (Stanley & Bhatt, Expert Opin Pharmacother 2012).
FDA-approved
2 mg/day
26+ weeks
Established efficacy for visceral fat
Off-label standard
12-26 weeks
Most common anti-aging clinic protocol
Conservative start
1 mg/day x 2 weeks, then 2 mg/day
Reduces initial side effects
Cost-conscious
1 mg/day ongoing
Lower efficacy but more affordable
Use the peptide cost calculator to compare the per-month expense of different dosing protocols.
Injection Protocol and Timing
Tesamorelin is injected subcutaneously once daily. The injection technique is identical to other peptide injections. If you are new to self-injection, our getting started with peptides guide walks through the complete process.
When to Inject
Inject in the morning on an empty stomach for optimal GH response. Growth hormone release is blunted by elevated blood glucose and insulin. Food, especially carbohydrates, raises both. Injecting fasted ensures the pituitary responds maximally to the GHRH stimulus.
Wait at least 15 to 30 minutes after injection before eating. This window allows the GH pulse to peak. Eating immediately after injection raises insulin, which opposes GH secretion and partially negates the lipolytic effect.
The Egrifta prescribing information specifies injection "before breakfast" for this reason. While evening injection is technically possible, the largest natural GH pulse occurs during the first hours of sleep. Adding a morning tesamorelin pulse creates a second daily GH peak, maximizing the total daily GH exposure without interfering with nocturnal physiology.
Injection Sites and Rotation
The FDA-approved injection site is the abdomen. Inject at least 2 inches from the navel. Rotate between different abdominal quadrants each day to prevent injection site reactions and lipohypertrophy.
Standard rotation pattern for daily injections:
Day 1: Upper right abdomen
Day 2: Lower right abdomen
Day 3: Upper left abdomen
Day 4: Lower left abdomen
Day 5: Repeat cycle
Avoid injecting into scar tissue, bruises, or areas of skin irritation. The needle gauge for tesamorelin is typically 29 to 31 gauge, the same insulin syringes used for other subcutaneous peptides.
Tesamorelin Cycling Protocols
Because visceral fat returns when tesamorelin is discontinued, cycling strategies aim to balance efficacy, cost, and long-term safety. There is no single "correct" cycle. The following protocols are based on clinical data and practitioner consensus.
Standard 12-Week Cycle
The most common off-label protocol:
Active
12 weeks
Full therapeutic dose
Off
4-8 weeks
None
Monitor body composition
Repeat
As needed
Resume if visceral fat increases
Twelve weeks provides roughly half the visceral fat reduction seen at 26 weeks in the Phase 3 trials. The off period allows the pituitary to reset and prevents potential desensitization of GHRH receptors. In practice, most users report retaining a portion of the fat loss during the off period, particularly if they maintain a caloric deficit and regular exercise.
Extended 26-Week Protocol
This mirrors the Phase 3 trial duration and produces the full 15 to 18% visceral fat reduction. It is the best-studied timeframe.
26 weeks
8-12 weeks
Reassess
After off period
CT scan or DEXA to measure visceral fat
The longer off period (8 to 12 weeks) accounts for the fact that the 52-week extension data showed fat reaccumulation begins within weeks of stopping. A longer active phase followed by a generous off period provides the best balance between results and recovery.
The peptide half-life tracker can help you understand how quickly tesamorelin clears your system after the last injection.
5-Day On, 2-Day Off Protocol
Some practitioners recommend injecting Monday through Friday and resting on weekends. The rationale: reducing total weekly exposure by approximately 30% while maintaining most of the lipolytic stimulus.
No clinical trial has tested this specific schedule. The pharmacokinetic rationale is tenuous: tesamorelin has a half-life of about 26 minutes, so the peptide itself clears rapidly regardless. The effect depends on the downstream GH pulse, which lasts several hours. Missing two days per week likely reduces cumulative GH exposure meaningfully.
This protocol is reasonable for cost management but probably sacrifices some efficacy. If budget is the primary constraint, a lower daily dose (1 mg/day, 7 days per week) may produce more consistent results than an interrupted schedule.
Tesamorelin vs Other GH-Releasing Peptides
Tesamorelin is one of several peptides that increase growth hormone levels. Each works through a different mechanism, and the choice depends on your goals, budget, and risk tolerance. For a comprehensive comparison of all peptides used for body composition, see our best peptides for weight loss guide.
Tesamorelin vs CJC-1295/Ipamorelin
CJC-1295 (with DAC) is a modified GHRH analog with a dramatically longer half-life (5 to 8 days) due to its Drug Affinity Complex. It is often combined with ipamorelin, a growth hormone-releasing peptide (GHRP) that acts on ghrelin receptors rather than GHRH receptors.
GHRH receptor agonist
GHRH + ghrelin receptor agonist
Half-life
~26 minutes
CJC: 5-8 days; Ipamorelin: ~2 hours
GH release pattern
Single pulsatile burst
Sustained elevation (CJC) + pulse (Ipa)
FDA approval
Yes (for HIV lipodystrophy)
No
Clinical trial data
Phase 3 (800+ participants)
Limited human data
Visceral fat data
15-18% reduction (CT-verified)
No CT-verified fat loss data
Typical dose
2 mg/day SC
CJC: 2 mg/week; Ipa: 200-300 mcg 2-3x/day
Cost (approximate)
The critical advantage of tesamorelin is evidence quality. Its visceral fat reduction was measured by CT scan in randomized, placebo-controlled trials with hundreds of participants. CJC-1295/ipamorelin has anecdotal support and small studies but nothing approaching that level of evidence (Ionescu & Bhatt, Expert Opin Biol Ther 2015).
The critical advantage of CJC-1295/ipamorelin is cost. It runs roughly one-third the monthly price of tesamorelin at research-grade pricing. For users prioritizing affordability over evidence certainty, the combination is a practical alternative.
Tesamorelin vs Sermorelin
Sermorelin is the first 29 amino acids of natural GHRH. It was FDA-approved for pediatric growth hormone deficiency (brand name Geref) but was discontinued in 2008 for commercial reasons, not safety concerns.
Structure
Modified GHRH (1-44) with hexenoic acid
GHRH (1-29)
~11 minutes
FDA status
Approved (Egrifta)
Discontinued (Geref)
Fat loss data
Phase 3 trial data
No fat-specific trial data
200-500 mcg/day
Cost
Sermorelin's shorter half-life means it produces a weaker GH pulse per injection. The hexenoic acid modification on tesamorelin is specifically what gives it the pharmacokinetic edge. For fat loss, tesamorelin is the stronger choice when budget allows. For general anti-aging and GH optimization on a budget, sermorelin remains popular in clinical practice.
For dosing details on other GH secretagogues, see our guides on hexarelin dosage and MOTS-c peptide dosage.
Tesamorelin vs Retatrutide and GLP-1 Agonists
Tesamorelin and GLP-1 agonists reduce body fat through entirely different pathways. Comparing them directly is like comparing a scalpel to a sledgehammer: both remove material, but the precision and mechanism are unrelated.
Increases GH, targets visceral fat
Suppresses appetite, slows gastric emptying
Fat type targeted
Visceral (preferentially)
Total body fat (non-selective)
Weight loss
Modest (~0.5-1 kg over 26 weeks)
Significant (10-15%+ body weight)
Lean mass effect
Preserves or increases
May reduce lean mass
Appetite effect
Minimal
Strong suppression
Daily burden
Daily injection
Weekly injection (semaglutide)
Tesamorelin does not cause significant total weight loss. It reduces visceral fat specifically while preserving lean mass. GLP-1 agonists produce large-scale weight loss that includes both fat and some lean tissue.
For individuals whose primary concern is visceral fat around the organs (the metabolically active fat linked to cardiovascular disease and insulin resistance) rather than total body weight, tesamorelin addresses the specific problem. For those who need substantial overall weight reduction, GLP-1 agonists or triple agonists like retatrutide are more appropriate. Some practitioners combine both approaches. For peptide combination strategies, see the peptide stacking guide.
How to Reconstitute Tesamorelin
Research-grade tesamorelin arrives as a lyophilized (freeze-dried) powder in vials typically containing 2 mg or 5 mg. The commercial product (Egrifta SV) comes as a single-use kit with prefilled diluent, but research vials require manual reconstitution.
For a detailed comparison of diluents, see bacteriostatic water vs sterile water.
Supplies Needed
Tesamorelin vial
Lyophilized powder (2 mg or 5 mg)
Bacteriostatic water
0.9% benzyl alcohol preserved
Insulin syringes
29-31 gauge, 0.5 mL or 1 mL
Alcohol swabs
For cleaning vial tops and injection sites
Always use bacteriostatic water for multi-dose vials. The benzyl alcohol preservative prevents bacterial growth and allows the reconstituted solution to last 28 to 30 days when refrigerated. Sterile water contains no preservative and must be used within 24 to 48 hours. For sourcing, see where to buy bacteriostatic water for injection.
Reconstitution Steps
1.Clean the rubber stoppers on both the tesamorelin vial and the bacteriostatic water vial with alcohol swabs. Allow to dry.
2.Draw your chosen volume of bacteriostatic water into the syringe. For a 2 mg vial, use 0.5 mL for a concentration of 4 mg/mL (convenient for a 2 mg dose = 0.5 mL). For a 5 mg vial, use 1 mL for a concentration of 5 mg/mL.
3.Insert the needle into the tesamorelin vial at a slight angle. Let the water flow slowly down the inside wall of the glass. Never spray directly onto the lyophilized cake.
4.Swirl the vial gently in a circular motion. Do not shake. Shaking creates foam, denatures the peptide, and reduces potency.
5.Wait until fully dissolved. The solution should be clear and colorless. If you see particles, refrigerate for 15 minutes and swirl again.
6.Label the vial with the reconstitution date and concentration.
7.Store immediately at 2 to 8 degrees Celsius (standard refrigerator temperature).
Use the reconstitution calculator to determine exact volumes for any vial size.
Dosing After Reconstitution
With a 2 mg vial reconstituted in 0.5 mL bacteriostatic water (4 mg/mL):
1 mg
0.25 mL
25 units
2 mg
0.50 mL
50 units
With a 5 mg vial reconstituted in 1 mL bacteriostatic water (5 mg/mL):
0.20 mL
20 units
5 doses
0.40 mL
40 units
2.5 doses
The 5 mg vial offers better value per milligram, but at the standard 2 mg/day dose, a single vial lasts only 2.5 days. This means frequent reconstitution. Some users reconstitute several vials at once and rotate through them during the week. For storage guidelines and shelf life of reconstituted peptides, see how long do reconstituted peptides last and does bacteriostatic water need to be refrigerated.
Side Effects of Tesamorelin
Tesamorelin has a well-characterized safety profile from Phase 3 trials involving over 800 participants and post-marketing surveillance since its 2010 FDA approval. The side effect profile is milder than exogenous growth hormone, consistent with its mechanism of stimulating physiological GH release rather than overriding it.
Common Side Effects
The most frequently reported adverse events from the Phase 3 trials (Falutz et al., NEJM 2007; Dhillon, Drugs 2011):
Injection site reactions (erythema, pruritus)
8.5%
3.0%
Arthralgia (joint pain)
6.1%
3.8%
Peripheral edema
5.5%
2.7%
Myalgia (muscle pain)
3.6%
1.8%
Paresthesia (tingling/numbness)
3.5%
1.2%
Nausea
2.5%
1.9%
Injection site reactions are the most common complaint. They are typically mild: redness, itching, or a small bump at the injection site that resolves within hours. Rotating injection sites daily minimizes this issue.
Joint pain and edema are growth hormone-mediated effects. They occur because GH increases fluid retention and stimulates tissue growth. These effects are dose-dependent and generally resolve within the first 4 to 6 weeks as the body adapts. If persistent, they may indicate IGF-1 levels above the desired range.
IGF-1 Monitoring
Tesamorelin raises IGF-1 levels by an average of 81 ng/mL over 26 weeks. The prescribing information recommends measuring IGF-1 at baseline and during treatment. If IGF-1 exceeds 3 standard deviations above the age-adjusted mean, discontinuation should be considered (Egrifta SV Prescribing Information, 2023).
In practice, most anti-aging practitioners check IGF-1 at baseline, 6 weeks, and 12 weeks. A target IGF-1 range of 200 to 300 ng/mL for adults under 50 (or the upper third of the age-adjusted reference range) is commonly used.
Elevated IGF-1 is not inherently dangerous in the short term, but chronically elevated levels are associated with increased cancer risk in epidemiological studies. This is why cycling tesamorelin (rather than continuous indefinite use) is the preferred approach for off-label fat loss protocols.
Contraindications
Tesamorelin is contraindicated in the following populations per the FDA label:
Active malignancy: GH and IGF-1 can promote tumor growth. Do not use tesamorelin if you have an active cancer diagnosis.
Pregnancy: Tesamorelin is classified as pregnancy category X. It has demonstrated fetal harm in animal studies.
Disruption of the hypothalamic-pituitary axis: Conditions such as pituitary surgery, radiation, or head trauma may prevent the pituitary from responding to GHRH stimulation, rendering tesamorelin ineffective.
Known hypersensitivity: Allergy to tesamorelin or mannitol (an excipient in the formulation).
Additionally, patients with a history of pituitary tumors should avoid tesamorelin. For a complete overview of peptide contraindications and drug interactions, see the peptide safety guide.
Clinical Evidence Beyond HIV Lipodystrophy
While the FDA approval is specific to HIV lipodystrophy, several studies have examined tesamorelin's effects in broader metabolic contexts. The data supports its role in visceral fat reduction regardless of HIV status, though the evidence base is smaller.
Non-Alcoholic Fatty Liver Disease (NAFLD)
A randomized, double-blind trial of 61 HIV-positive patients with NAFLD and hepatic steatosis found that tesamorelin 2 mg/day for 12 months significantly reduced liver fat content (measured by MRI spectroscopy) and prevented progression of hepatic fibrosis (Stanley et al., Ann Intern Med 2014).
Liver fat decreased by 37% in the tesamorelin group versus an increase of 7% in the placebo group. The number of patients with hepatic steatosis resolution (liver fat below 5%) was 35% in the tesamorelin group versus 4% in placebo.
This finding is significant because visceral fat and liver fat are metabolically linked. Reducing visceral adiposity improves hepatic lipid metabolism, potentially slowing or reversing fatty liver disease.
Cardiovascular Risk Markers
Pooled analysis of the Phase 3 trials showed that tesamorelin reduced triglycerides by approximately 50 mg/dL and improved the ratio of trunk fat to limb fat, a surrogate marker for cardiometabolic risk (Falutz et al., JAIDS 2010).
A subsequent study found that 12 months of tesamorelin reduced carotid intima-media thickness (cIMT), an established predictor of atherosclerotic cardiovascular disease, in HIV-positive individuals with increased visceral fat (Fourman et al., J Clin Endocrinol Metab 2020).
These findings suggest that tesamorelin's visceral fat reduction translates into meaningful cardiovascular risk reduction, though no trial has yet measured hard cardiovascular endpoints (heart attack, stroke).
Cognitive Function
An unexpected finding emerged from a separate line of research: tesamorelin may improve cognitive function in older adults. A randomized, double-blind trial of 152 cognitively normal adults aged 55 to 87 found that tesamorelin 1 mg/day for 20 weeks improved executive function, verbal memory, and processing speed compared to placebo (Baker et al., Arch Neurol 2012).
The mechanism is likely IGF-1-mediated. IGF-1 receptors are abundant in the hippocampus and prefrontal cortex, regions critical for memory and executive function. Whether these cognitive benefits are sustained with longer treatment or translate into reduced dementia risk remains unknown.
Practical Considerations: Storage, Sourcing, and Cost
Tesamorelin is among the more expensive peptides in the GH secretagogue category. Understanding the practical realities of sourcing, storage, and cost helps set realistic expectations.
Storage Requirements
Lyophilized powder (unreconstituted)
Room temperature or refrigerated
12-24 months (per manufacturer)
Reconstituted with BAC water
Refrigerated (2-8 degrees C)
28-30 days
Reconstituted with sterile water
Refrigerated
24-48 hours
Never freeze reconstituted tesamorelin. Freezing can cause the peptide to denature and lose potency. Protect from light and temperature fluctuations. For comprehensive peptide storage protocols, see how to store peptides and how long does bacteriostatic water last.
Sourcing
Egrifta SV (the commercial product) is available by prescription and typically covered by insurance for HIV lipodystrophy. Without insurance, the retail price exceeds $1,000 per month.
Research-grade tesamorelin is available from peptide suppliers at lower cost, though quality varies significantly between vendors. Third-party testing (HPLC purity and mass spectrometry verification) is essential when purchasing from research suppliers. For guidance on evaluating peptide vendors, see where to buy peptides 2026. Note that the FDA peptide crackdown 2026 has affected the availability and legality of certain research peptides.
Cost Optimization Strategies
At 2 mg/day, a 30-day supply of research-grade tesamorelin ranges from $200 to $500 depending on the vendor and vial size. Several strategies reduce cost:
Buy larger vials. A single 10 mg vial is typically cheaper per milligram than five 2 mg vials.
Cycle rather than use continuously. A 12-week cycle with a 4-week off period reduces annual peptide consumption by approximately 25%.
Consider the 1 mg/day protocol. If budget is the limiting factor, 1 mg/day halves the cost while still producing some GH elevation and lipolytic effect.
Compare using the peptide cost calculator. Input your dose, frequency, and vial size to see the true monthly and annual cost.
For related peptide options at different price points, compare with follistatin 344 dosage and GHK-Cu injection dosage.
Maximizing Fat Loss Results with Tesamorelin
Tesamorelin provides the hormonal stimulus for visceral fat mobilization, but your results will scale with the metabolic environment you create around it. The peptide opens the door; your habits determine how far you walk through it.
Fasted Morning Cardio
Injecting tesamorelin on an empty stomach triggers a GH pulse within 15 to 30 minutes. Growth hormone mobilizes fatty acids from visceral adipose stores into the bloodstream. Performing low-to-moderate intensity cardiovascular exercise during this window burns those mobilized fatty acids before they are re-esterified and stored again.
The combination of fasted tesamorelin injection followed by 30 to 45 minutes of walking, cycling, or light jogging is the most commonly recommended protocol among practitioners who prescribe tesamorelin for body composition. No controlled trial has tested this specific combination, but the physiological rationale is sound: GH mobilizes fat, exercise oxidizes it.
Avoid high-intensity exercise immediately after injection. Intense exercise raises cortisol, which opposes GH-mediated lipolysis and promotes visceral fat storage (Djurhuus et al., Am J Physiol Endocrinol Metab 2004). Moderate intensity is the sweet spot.
Dietary Considerations
Tesamorelin does not suppress appetite. Unlike GLP-1 agonists, you will not feel less hungry. This means dietary discipline remains entirely your responsibility.
A moderate caloric deficit (300 to 500 calories below maintenance) amplifies tesamorelin's fat-reducing effect. The peptide preferentially mobilizes visceral fat; a caloric deficit ensures those mobilized fatty acids are burned rather than redistributed.
Protein intake is critical. Tesamorelin preserves and may slightly increase lean body mass, but only if sufficient amino acids are available. Aim for 1.6 to 2.2 g of protein per kilogram of body weight daily, consistent with current recommendations for body recomposition.
Minimize refined carbohydrates and sugar, especially in the morning after injection. Insulin spikes counteract GH signaling. A protein-and-fat breakfast (consumed 30 or more minutes after injection) maintains the favorable hormonal environment.
Sleep Optimization
Growth hormone secretion peaks during slow-wave sleep (deep sleep). Tesamorelin adds a morning GH pulse; you want the nocturnal pulse to remain strong. Poor sleep blunts nighttime GH release, reducing the total daily GH exposure.
Practical sleep priorities for tesamorelin users:
7 to 9 hours per night. Consistently.
Consistent sleep and wake times. Circadian rhythm regularity supports GH pulsatility.
Avoid late-night eating. Insulin and blood glucose suppress nocturnal GH release.
Limit alcohol. Alcohol disrupts slow-wave sleep architecture and reduces GH secretion by up to 75% (Van Cauter et al., Lancet 1999).
For guidance on peptides that support gut health and overall recovery alongside a fat loss protocol, see peptides for gut health.
Tesamorelin Dosage FAQ
Frequently Asked Questions
The established dose is 2 mg (2,000 mcg) injected subcutaneously once daily, preferably in the morning on an empty stomach. This is the FDA-approved dose that produced 15 to 18% visceral fat reduction in Phase 3 trials of over 800 participants. No titration is required.
Measurable visceral fat reduction appears within 8 to 12 weeks, with the full effect at 26 weeks. In the pivotal trials, CT scans showed a 15 to 18% reduction in visceral adipose tissue after 26 weeks of daily 2 mg injections. Some practitioners report visible abdominal changes as early as 6 weeks.
The physiological mechanism (stimulating pituitary GH release to increase visceral fat lipolysis) is not HIV-specific. However, the Phase 3 data was collected exclusively in HIV-positive populations. Off-label use in non-HIV patients is common in anti-aging clinics, but controlled trial data in the general population is limited.
Some practitioners combine tesamorelin (GHRH agonist) with ipamorelin (GHRP/ghrelin agonist) for a synergistic GH release. The rationale is that stimulating both the GHRH and ghrelin pathways simultaneously produces a larger GH pulse than either alone. No clinical trial has studied this combination for fat loss.
Visceral fat returns. The 52-week extension study showed that participants who switched from tesamorelin to placebo at week 26 regained their visceral fat within 3 months. Ongoing or cyclical use is necessary to maintain results, and lifestyle factors like diet and exercise influence the rate of reaccumulation.
Mild peripheral edema (fluid retention) occurs in approximately 5.5% of users, compared to 2.7% on placebo. This is a growth hormone-mediated effect that typically resolves within the first 4 to 6 weeks. Reducing sodium intake and staying well-hydrated can help manage it. Persistent edema may indicate IGF-1 levels above the target range.
Tesamorelin has stronger evidence: Phase 3 trials with CT-verified visceral fat reduction in over 800 participants. CJC-1295 has limited human data and no CT-verified fat loss studies. However, CJC-1295 costs roughly one-third as much. If evidence quality is the priority, tesamorelin wins. If budget is the constraint, CJC-1295/ipamorelin is a reasonable alternative.
Refrigerate at 2 to 8 degrees Celsius. When reconstituted with bacteriostatic water, the solution remains stable for 28 to 30 days. Do not freeze reconstituted tesamorelin. Protect from light. Discard if the solution appears cloudy or contains visible particles after gentle swirling.
The Bottom Line
Tesamorelin stands alone among GH-releasing peptides: it is the only one with FDA approval, Phase 3 trial data, and CT-verified evidence that it reduces visceral fat by 15 to 18% over 26 weeks. The dose is straightforward. Inject 2 mg subcutaneously once daily, in the morning, on an empty stomach. No titration required.
The clinical evidence is clear on what tesamorelin does and what it does not do. It selectively reduces the deep visceral fat that wraps around your organs and drives metabolic disease. It does not produce dramatic scale weight loss. It preserves lean body mass. And when you stop, the fat returns, so plan for cycling or ongoing use from the start.
Pair the peptide with fasted morning cardio, adequate protein intake, quality sleep, and a moderate caloric deficit. These habits amplify the hormonal signal tesamorelin provides.
For reconstitution volumes, use the reconstitution calculator. For cost planning, use the peptide cost calculator. For tracking clearance between cycles, use the peptide half-life tracker. For safe storage practices, see how to store peptides and how long do reconstituted peptides last. For peptide sourcing guidance, see where to buy peptides 2026. For broader safety context, read the peptide safety guide and FDA peptide crackdown 2026. For weight loss peptide comparisons, see best peptides for weight loss and retatrutide vs tirzepatide. Explore all peptide profiles, calculators, and research tools at PeptidesExplorer.